Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

QUANG NGUYEN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1053516542
CMS profile
535752
Location
HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$49,081.01

345 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

QUANG NGUYEN

NPI 1053516542 · CMS profile ID 535752

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

HENDERSON, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053516542?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
QUANG NGUYEN, NPI 1053516542, CMS profile ID 535752. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053516542?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). QUANG NGUYEN, NPI 1053516542, CMS profile ID 535752. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053516542?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
QUANG NGUYEN, NPI 1053516542, CMS profile ID 535752, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1053516542?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

345 matching records · $49,081.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 345 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 345.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $17.1709/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899377339 CMS
AstraZeneca Pharmaceuticals LP $17.1409/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915740005 CMS
Xeris Pharmaceuticals, Inc. $14.7709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946489237 CMS
Mannkind Corporation $20.5909/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942762523 CMS
Medtronic, Inc. $12.6409/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930328473 CMS
AstraZeneca Pharmaceuticals LP $17.4409/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914861209 CMS
Medtronic, Inc. $7.2309/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930328479 CMS
Abbott Laboratories $23.9109/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920384113 CMS
Lilly USA, LLC $0.8309/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918258433 CMS
Antares Pharma, Inc. $15.8308/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956870201 CMS
Lilly USA, LLC $18.7508/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918250671 CMS
Novo Nordisk Inc $19.7608/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898853147 CMS
Medtronic, Inc. $22.5708/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930328453 CMS
Abbott Laboratories $19.4708/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920384107 CMS
Horizon Therapeutics plc $19.2808/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937667181 CMS
ABBVIE INC. $9.0408/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891255807 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.2308/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930051249 CMS
Biohaven Pharmaceutical Holding Company Ltd. $13.0808/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923687003 CMS
IBSA Pharma Inc. $17.8608/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890038739 CMS
Corcept Therapeutics $26.1308/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948809703 CMS
Amgen Inc. $14.2508/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939246917 CMS
Amgen Inc. $13.5808/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939246931 CMS
PFIZER INC. $16.3108/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949230039 CMS
Novo Nordisk Inc $18.2308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898853133 CMS
Esperion Therapeutics, Inc. $16.2908/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947273783 CMS
AstraZeneca Pharmaceuticals LP $20.6508/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914639067 CMS
Lilly USA, LLC $119.9908/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918258431 CMS
Xeris Pharmaceuticals, Inc. $18.9408/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946489235 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.1108/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887777515 CMS
ABBVIE INC. $14.5408/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891255805 CMS
Medtronic, Inc. $5.2808/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930328459 CMS
Amryt Pharma Holdings Ltd $18.6308/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 881046371 CMS
Abbott Laboratories $27.2008/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920384123 CMS
Abbott Laboratories $26.8708/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908544557 CMS
Abbott Laboratories $4.9608/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908544563 CMS
Becton, Dickinson and Company $13.7908/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946086935 CMS
Becton, Dickinson and Company $13.8008/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946086995 CMS
Mannkind Corporation $15.9108/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942762521 CMS
AstraZeneca Pharmaceuticals LP $18.9908/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914748797 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.0507/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887362441 CMS
Novartis Pharmaceuticals Corporation $125.0007/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894026141 CMS
Biohaven Pharmaceutical Holding Company Ltd. $14.8207/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923687001 CMS
Xeris Pharmaceuticals, Inc. $13.8107/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946489233 CMS
Esperion Therapeutics, Inc. $14.9707/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947273779 CMS
Corcept Therapeutics $20.8307/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948809651 CMS
Amgen Inc. $8.4607/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939246929 CMS
Lilly USA, LLC $19.7607/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918228151 CMS
Medtronic, Inc. $14.2507/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930328445 CMS
Abbott Laboratories $21.0607/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920384109 CMS
Abbott Laboratories $4.6007/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920384129 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,147.30 338
PY2020 $78,886.69 371
PY2021 $78,235.00 399
PY2022 $49,081.01 345
PY2023 $22,950.37 199
PY2024 $18,470.04 200
PY2025 $28,828.30 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $14,416.09 5
PY2025 Principal investigator $1,056,795.71 28
PY2024 Recipient $65,767.77 3
PY2024 Principal investigator $278,532.02 22
PY2023 Principal investigator $536,888.15 34
PY2022 Principal investigator $219,304.90 82
PY2021 Principal investigator $142,733.00 14
PY2020 Principal investigator $202,215.81 22
PY2019 Principal investigator $79,838.80 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Novartis Pharmaceuticals Corporation $2,315.00 12/16/2025 Covered Recipient Physician A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190291532
Principal investigator 1 Dexcom, Inc. $57,702.00 10/28/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
EVAULATION OF THE DATA DELIVERY RELIABILITY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM No dispute reported 06/30/2026 1250961814
Principal investigator 1 Novartis Pharmaceuticals Corporation $735.95 09/29/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190307521
Recipient Novartis Pharmaceuticals Corporation $5,000.00 09/25/2025 Covered Recipient Physician A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190293207
Principal investigator 1 Eli Lilly and Company $982.63 08/26/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886256
Principal investigator 1 Globus Medical, Inc. $833.30 08/07/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236866220
Principal investigator 1 Dexcom, Inc. $3,100.00 07/22/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961802
Principal investigator 1 Dexcom, Inc. $1,700.00 07/22/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961806
Principal investigator 1 Dexcom, Inc. $52,817.00 07/08/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961804
Principal investigator 1 Dexcom, Inc. $23,160.00 07/08/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961810
Principal investigator 1 Dexcom, Inc. $3,500.00 07/01/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961808
Principal investigator 1 Dexcom, Inc. $21,841.00 07/01/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
EVALUATION OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM SURVIVABILITY AND DATA DELIVERY RELIABILITY IN ADULTS AND PEDIATRICS WITH TYPE 1 AND TYPE 2 DIABETES No dispute reported 06/30/2026 1250961812
Principal investigator 1 Eli Lilly and Company $104,252.00 06/10/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187884392
Principal investigator 1 Globus Medical, Inc. $29,328.00 05/29/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236866043
Principal investigator 1 Globus Medical, Inc. $11,364.00 05/13/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236865711
Principal investigator 1 Eli Lilly and Company $1,972.70 05/06/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187886364
Principal investigator 1 Globus Medical, Inc. $866.30 04/23/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236866564
Recipient Eli Lilly and Company $664.18 04/22/2025 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187873143
Principal investigator 1 Amgen Inc. $149,883.19 03/11/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246643483
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,925.10 02/27/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312451
Principal investigator 1 Dexcom, Inc. $4,275.00 02/25/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961820
Principal investigator 1 Dexcom, Inc. $6,575.00 02/18/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961816
Principal investigator 1 Dexcom, Inc. $1,100.00 02/18/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961818
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,312.67 02/05/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312453
Principal investigator 1 Dexcom, Inc. $3,525.00 02/04/2025 Non-covered Recipient Entity
Las Vegas Endocrinology
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961822
Principal investigator 1 Eli Lilly and Company $325,806.00 02/04/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187884348
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,713.30 01/30/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311723
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,048.22 01/27/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307517
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,228.87 01/24/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190307519
Recipient Eli Lilly and Company $2,931.87 01/17/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187872679
Recipient Eli Lilly and Company $3,505.04 01/17/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187876959
Principal investigator 1 Eli Lilly and Company $128,751.00 01/07/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884704
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,497.48 01/06/2025 Non-covered Recipient Entity
LAS VEGAS ENDOCRINOLOGY
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307515